Ultragenyx Capex To Revenue vs Pb Ratio Analysis

RARE Stock

USD 47.24 1.22 2.65%

Ultragenyx financial indicator trend analysis is much more than just breaking down Ultragenyx prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ultragenyx is a good investment. Please check the relationship between Ultragenyx Capex To Revenue and its Pb Ratio accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ultragenyx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Ultragenyx Stock refer to our How to Trade Ultragenyx Stock guide.

Capex To Revenue vs Pb Ratio

Capex To Revenue vs Pb Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ultragenyx Capex To Revenue account and Pb Ratio. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Ultragenyx's Capex To Revenue and Pb Ratio is 0.46. Overlapping area represents the amount of variation of Capex To Revenue that can explain the historical movement of Pb Ratio in the same time period over historical financial statements of Ultragenyx, assuming nothing else is changed. The correlation between historical values of Ultragenyx's Capex To Revenue and Pb Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Revenue of Ultragenyx are associated (or correlated) with its Pb Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Pb Ratio has no effect on the direction of Capex To Revenue i.e., Ultragenyx's Capex To Revenue and Pb Ratio go up and down completely randomly.

Correlation Coefficient

0.46

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Pb Ratio

Most indicators from Ultragenyx's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ultragenyx current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ultragenyx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Ultragenyx Stock refer to our How to Trade Ultragenyx Stock guide.The current year's Selling General Administrative is expected to grow to about 325.3 M, whereas Tax Provision is projected to grow to (1.7 M).

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	13.2M	18.2M	26.0M	16.3M
Interest Income	1.9M	11.1M	26.7M	28.0M

Reconciled Depreciation Interest Income

Ultragenyx fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Property Plant Equipment	Short Term Investments
Total Assets		0.82	0.84	0.77	0.7	0.74	-0.74	-0.82	0.69	0.77	0.84	0.17	0.76	0.95	0.66	0.93	0.96	0.74	0.95	0.89	0.77	0.71	0.96	0.93	0.68	0.92
Other Current Liab	0.82		1.0	0.46	0.96	0.97	-0.44	-0.99	0.95	0.49	0.97	0.48	0.93	0.7	0.94	0.79	0.87	0.96	0.78	0.98	0.98	0.96	0.73	0.81	0.96	0.77
Total Current Liabilities	0.84	1.0		0.47	0.96	0.97	-0.46	-0.99	0.95	0.5	0.98	0.48	0.93	0.72	0.92	0.8	0.88	0.96	0.8	0.98	0.98	0.96	0.74	0.81	0.95	0.79
Total Stockholder Equity	0.77	0.46	0.47		0.23	0.29	-0.86	-0.42	0.22	0.86	0.5	-0.16	0.41	0.89	0.26	0.72	0.66	0.28	0.76	0.61	0.32	0.25	0.87	0.72	0.21	0.73
Other Liab	0.7	0.96	0.96	0.23		0.99	-0.29	-0.96	0.98	0.34	0.93	0.6	0.89	0.55	0.97	0.65	0.76	1.0	0.64	0.9	0.99	0.98	0.58	0.67	0.99	0.66
Property Plant And Equipment Net	0.74	0.97	0.97	0.29	0.99		-0.29	-0.97	0.97	0.35	0.96	0.57	0.95	0.6	0.94	0.69	0.8	0.99	0.71	0.92	0.99	1.0	0.61	0.71	0.99	0.71
Net Debt	-0.74	-0.44	-0.46	-0.86	-0.29	-0.29		0.4	-0.2	-1.0	-0.44	0.16	-0.3	-0.82	-0.31	-0.6	-0.58	-0.34	-0.63	-0.55	-0.37	-0.24	-0.85	-0.6	-0.22	-0.57
Retained Earnings	-0.82	-0.99	-0.99	-0.42	-0.96	-0.97	0.4		-0.96	-0.45	-0.98	-0.54	-0.93	-0.68	-0.95	-0.8	-0.89	-0.97	-0.79	-0.97	-0.98	-0.96	-0.7	-0.82	-0.96	-0.76
Accounts Payable	0.69	0.95	0.95	0.22	0.98	0.97	-0.2	-0.96		0.25	0.92	0.58	0.88	0.53	0.93	0.69	0.78	0.97	0.67	0.9	0.97	0.97	0.56	0.71	0.98	0.7
Cash	0.77	0.49	0.5	0.86	0.34	0.35	-1.0	-0.45	0.25		0.49	-0.11	0.36	0.85	0.36	0.63	0.62	0.39	0.66	0.6	0.42	0.3	0.87	0.63	0.27	0.61
Non Current Assets Total	0.84	0.97	0.98	0.5	0.93	0.96	-0.44	-0.98	0.92	0.49		0.55	0.96	0.72	0.9	0.8	0.89	0.94	0.82	0.97	0.95	0.95	0.72	0.81	0.93	0.77
Non Currrent Assets Other	0.17	0.48	0.48	-0.16	0.6	0.57	0.16	-0.54	0.58	-0.11	0.55		0.52	-0.03	0.64	0.17	0.28	0.57	0.16	0.43	0.55	0.6	0.0	0.19	0.61	0.15
Other Assets	0.76	0.93	0.93	0.41	0.89	0.95	-0.3	-0.93	0.88	0.36	0.96	0.52		0.65	0.86	0.71	0.82	0.9	0.75	0.91	0.91	0.95	0.62	0.73	0.92	0.71
Cash And Short Term Investments	0.95	0.7	0.72	0.89	0.55	0.6	-0.82	-0.68	0.53	0.85	0.72	-0.03	0.65		0.5	0.87	0.87	0.6	0.92	0.8	0.63	0.56	0.99	0.86	0.52	0.91
Net Receivables	0.66	0.94	0.92	0.26	0.97	0.94	-0.31	-0.95	0.93	0.36	0.9	0.64	0.86	0.5		0.64	0.74	0.95	0.59	0.89	0.95	0.94	0.55	0.67	0.96	0.59
Common Stock Total Equity	0.93	0.79	0.8	0.72	0.65	0.69	-0.6	-0.8	0.69	0.63	0.8	0.17	0.71	0.87	0.64		0.96	0.68	0.92	0.87	0.71	0.66	0.89	1.0	0.65	0.89
Common Stock Shares Outstanding	0.96	0.87	0.88	0.66	0.76	0.8	-0.58	-0.89	0.78	0.62	0.89	0.28	0.82	0.87	0.74	0.96		0.79	0.96	0.93	0.82	0.78	0.88	0.96	0.76	0.89
Non Current Liabilities Total	0.74	0.96	0.96	0.28	1.0	0.99	-0.34	-0.97	0.97	0.39	0.94	0.57	0.9	0.6	0.95	0.68	0.79		0.69	0.91	1.0	0.98	0.63	0.7	0.98	0.71
Other Current Assets	0.95	0.78	0.8	0.76	0.64	0.71	-0.63	-0.79	0.67	0.66	0.82	0.16	0.75	0.92	0.59	0.92	0.96	0.69		0.87	0.72	0.68	0.9	0.92	0.64	0.9
Other Stockholder Equity	0.89	0.98	0.98	0.61	0.9	0.92	-0.55	-0.97	0.9	0.6	0.97	0.43	0.91	0.8	0.89	0.87	0.93	0.91	0.87		0.93	0.9	0.82	0.88	0.89	0.84
Total Liab	0.77	0.98	0.98	0.32	0.99	0.99	-0.37	-0.98	0.97	0.42	0.95	0.55	0.91	0.63	0.95	0.71	0.82	1.0	0.72	0.93		0.98	0.66	0.73	0.98	0.73
Property Plant And Equipment Gross	0.71	0.96	0.96	0.25	0.98	1.0	-0.24	-0.96	0.97	0.3	0.95	0.6	0.95	0.56	0.94	0.66	0.78	0.98	0.68	0.9	0.98		0.57	0.68	0.99	0.68
Total Current Assets	0.96	0.73	0.74	0.87	0.58	0.61	-0.85	-0.7	0.56	0.87	0.72	0.0	0.62	0.99	0.55	0.89	0.88	0.63	0.9	0.82	0.66	0.57		0.88	0.54	0.91
Common Stock	0.93	0.81	0.81	0.72	0.67	0.71	-0.6	-0.82	0.71	0.63	0.81	0.19	0.73	0.86	0.67	1.0	0.96	0.7	0.92	0.88	0.73	0.68	0.88		0.67	0.89
Property Plant Equipment	0.68	0.96	0.95	0.21	0.99	0.99	-0.22	-0.96	0.98	0.27	0.93	0.61	0.92	0.52	0.96	0.65	0.76	0.98	0.64	0.89	0.98	0.99	0.54	0.67		0.65
Short Term Investments	0.92	0.77	0.79	0.73	0.66	0.71	-0.57	-0.76	0.7	0.61	0.77	0.15	0.71	0.91	0.59	0.89	0.89	0.71	0.9	0.84	0.73	0.68	0.91	0.89	0.65

Click cells to compare fundamentals

Ultragenyx Account Relationship Matchups

Ultragenyx fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.1B	1.8B	1.5B	1.5B	1.5B	856.5M
Other Current Liab	83.2M	140.9M	134.5M	192.9M	225.7M	237.0M
Total Current Liabilities	103.3M	189.6M	181.4M	261.2M	280.4M	294.5M
Total Stockholder Equity	653.8M	1.2B	922.6M	352.5M	275.4M	481.1M
Other Liab	348.7M	376.3M	387.6M	911.9M	1.0B	1.1B
Property Plant And Equipment Net	74.7M	114.0M	176.2M	285.7M	290.6M	305.1M
Net Debt	(396.6M)	(665.3M)	(265.6M)	(101.4M)	(170.4M)	(178.9M)
Retained Earnings	(1.4B)	(1.6B)	(2.1B)	(2.8B)	(3.4B)	(3.2B)
Accounts Payable	12.9M	12.9M	17.1M	43.3M	42.1M	44.2M
Cash	433.6M	713.5M	307.6M	132.9M	213.6M	202.9M
Non Current Assets Total	284.5M	464.3M	665.8M	661.5M	758.8M	796.8M
Non Currrent Assets Other	(4.2M)	(24.5M)	11.6M	10.7M	57.7M	60.6M
Other Assets	3.5M	8.8M	20.6M	16.8M	19.4M	20.3M
Cash And Short Term Investments	760.4M	1.2B	999.1M	896.7M	577.2M	543.4M
Net Receivables	32.8M	23.1M	28.4M	40.4M	73.4M	77.1M
Common Stock Total Equity	58K	67K	69K	70K	80.5K	44.1K
Common Stock Shares Outstanding	56.6M	60.8M	67.8M	69.9M	73.5M	50.9M
Liabilities And Stockholders Equity	1.1B	1.8B	1.5B	1.5B	1.5B	856.5M
Non Current Liabilities Total	378.4M	415.6M	418.5M	931.7M	935.2M	981.9M
Other Current Assets	46.2M	57.6M	71.7M	68.9M	47.6M	34.5M
Other Stockholder Equity	2.1B	2.8B	3.0B	3.1B	3.7B	3.8B
Total Liab	481.7M	605.2M	599.8M	1.2B	1.2B	1.3B
Property Plant And Equipment Gross	74.7M	114.0M	226.2M	349.1M	374.0M	392.7M
Total Current Assets	851.0M	1.3B	856.6M	883.9M	732.2M	564.7M
Accumulated Other Comprehensive Income	(147K)	689K	(1.4M)	(6.6M)	647K	679.4K
Common Stock	58K	67K	69K	70K	82K	47.6K
Property Plant Equipment	74.7M	73.5M	141.2M	259.7M	298.7M	313.6M
Short Term Investments	321.6M	488.0M	432.6M	614.8M	363.6M	347.3M
Net Tangible Assets	480.4M	978.9M	758.4M	148.0M	170.2M	161.7M
Retained Earnings Total Equity	(1.4B)	(1.6B)	(2.1B)	(2.8B)	(2.5B)	(2.4B)
Capital Surpluse	2.1B	2.8B	3.0B	3.1B	3.6B	2.0B
Inventory	11.5M	13.0M	16.2M	26.8M	34.0M	35.7M
Non Current Liabilities Other	345.1M	382.3M	385.2M	4.8M	12.2M	11.6M
Intangible Assets	129M	131.1M	130.8M	160.1M	166.3M	108.7M
Long Term Investments	32.9M	10.5M	258.9M	154.5M	199.9M	108.0M
Net Invested Capital	653.8M	1.2B	922.6M	352.5M	275.4M	497.3M
Net Working Capital	747.7M	1.1B	675.2M	622.7M	451.7M	667.7M
Capital Stock	58K	67K	69K	70K	82K	72.8K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Ultragenyx is a strong investment it is important to analyze Ultragenyx's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ultragenyx's future performance. For an informed investment choice regarding Ultragenyx Stock, refer to the following important reports:

How To Invest In Ultragenyx

Details

Is Ultragenyx Stock a good investment?

Details

What is Ultragenyx's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ultragenyx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Ultragenyx Stock refer to our How to Trade Ultragenyx Stock guide.

You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ultragenyx. If investors know Ultragenyx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ultragenyx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(6.35)

Revenue Per Share

6.015

Quarterly Revenue Growth

0.423

Return On Assets

(0.24)

Return On Equity

(2.90)

The market value of Ultragenyx is measured differently than its book value, which is the value of Ultragenyx that is recorded on the company's balance sheet. Investors also form their own opinion of Ultragenyx's value that differs from its market value or its book value, called intrinsic value, which is Ultragenyx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ultragenyx's market value can be influenced by many factors that don't directly affect Ultragenyx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Ultragenyx's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ultragenyx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ultragenyx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ultragenyx Capex To Revenue vs Pb Ratio Analysis

Capex To Revenue vs Pb Ratio

Capex To Revenue vs Pb Ratio Correlation Analysis

Correlation Coefficient

Capex To Revenue

Pb Ratio

Ultragenyx fundamental ratios Correlations

Ultragenyx Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Ultragenyx fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Liabilities	+ 1.0	Other Current Liab
Non Current Liabilities Total	+ 1.0	Other Liab
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Common Stock	+ 1.0	Common Stock Total Equity
Total Liab	+ 1.0	Non Current Liabilities Total
Property Plant And Equipment Net	+ 0.99	Other Liab

Cash	- 1.0	Net Debt
Retained Earnings	- 0.99	Total Current Liabilities
Retained Earnings	- 0.99	Other Current Liab
Total Liab	- 0.98	Retained Earnings
Non Current Assets Total	- 0.98	Retained Earnings
Other Stockholder Equity	- 0.97	Retained Earnings